The Gross law firm has filed a class action lawsuit against Bluebird on behalf of shareholders who purchased between April 24 2023 and December 8 2023.

IMO, Blue has not committed the securities law violations alleged (which have not been named or enumerated, btw), and any lawsuit going forward should be filed against the FDA for their issuance of the "Blackbox" warning. Blue stated previously they intend to address the non-award of the PRV with the FDA. They should also be pursuing removal of the "Blackbox" warning; if the Blackbox warning had teeth, the clinical trial hold should never have been lifted in the first place - but the FDA vindicated BLUE from this previously. Furthermore, if BLUE did commit securities fraud (again, unspecified how), then that falls onto the regulatory agency moreso than BLUE, IMO.

Honestly - if not a single analyst anticipated the Blackbox warning, this is all a malignant waste of time by the FDA.

[ALLEGATIONS: According to the complaint, on December 8, 2023, Blue announced that the Food and Drug Administration (FDA) approved its drug Lyfgenia (lovotibeglogene autotemcel), also known as lovo-cel for the treatment of sickle cell disease in patients ages 12 and older who have a history of vaso-occlusive events (VOEs). However, the Lyfgenia approval came with a black box warning for haematological malignancies after two patients developed AML during the clinical trials. Analysts noted that they did not expect the black box warning or the absence of a priority review voucher. Following this news, Blue's stock price fell by $1.95 per share, or approximately 40% to close at $2.86 per share.]

That seeking alpha article is behind a paywall, unfortunately. I'm sure I wouldn't be the only happy person if you posted the sentences that you find informative.

I believe in the power of BlueBird's medicines, but I am concerned about the shorts, as I've had a ridiculous amount of calls get just completely disintegrated by the pressure on this stock in the last 2.5 years. Hopefully, we find that Blue management is honest and also correct about their projections going forward. In addition to that, I'm keeping my fingers crossed that it is Hercules's goal to help facilitate the healthcare options that BLUE has created, and not to steal the entirety of the companies I.P. The agreement does hinge somewhat on the company trading, if I am correct in my calculations, above $2.63 USD for the preceding 30 days of the first day of any financial quarter.

I've lost out significantly to other companies' management teams over the years that were malignant, and I am deeply disturbed that BLUE eliminated the graphic of "Misc Undisclosed" from their pipeline page in the summer of '23. I'm disappointed they haven't addressed that, and have significant thoughts about addressing management over the issue myself. If any of these class action examinations have solid footing, that is one aspect that will be exposed.

I will be reducing my holdings, starting next week, by ~11% for tax harvesting purposes, but I am not going anywhere. I am hoping it tanks a bit more so I can keep more than 89% of my current holdings.

I have a hard time cheering someone who posts 4 month old info without a qualifier that it is 4 month old information. Couple that with your sudden appearance and flip from bearish to bullish within 3 weeks of each other....

Nov 7, 2023 at 8:00 AM EST has long since passed.

Why did you post this?

FDA Ramrod x2, + shorts.

Been with KOAN for years. This is an understatement:

[illiquid stinky pink company]

[On February 20, 2024, Resonate Blends, Inc. (the “Company”) entered into a Share Exchange Agreement (the “Exchange Agreement”) with Emergent Health Corp., a Wyoming corporation (hereinafter referred to as “EMGE”), and the holders (the “EMGE Preferred Shareholders) of Series Class A Preferred Stock, the Series C Convertible Non-Voting Preferred Stock and the Class F Preferred Stock of EMGE (the “EMGE Equity Interests”).]

https://www.otcmarkets.com/filing/html?id=17305421&guid=Hcd-k6NQcN5eJth

That would be lovely, but what's your info?

At 190.4mm shares to 20 per, that's 3.8 Billion - or over 1000 drug sales at 2.75m avg. BLUE forecasted 80-100 sales this year.

I believe the bottom has come and gone. I wouldn't expect to see anything below $0.95 again.

This guy wants your shares of BLUE ruhl bad, me thinks.

No, but they said it was still desired. From early/mid December: https://www.otcmarkets.com/filing/html?id=17119345&guid=2QJ-kn8STt5PB3h

I think it's pretty obvious that KOAN management is only concerned with enriching themselves.

What's that about BLUE?

"In connection with the approval of LYFGENIA, we did not receive a Rare Pediatric Disease Priority Review Voucher that we requested as part of the FDA’s review. We are evaluating the FDA’s denial and plan to dispute this decision with the FDA."

https://ih.advfn.com/stock-market/NASDAQ/bluebird-bio-BLUE/stock-news/92864211/form-424b5-prospectus-rule-424b5

That's one interpretation, for sure.

There should have been an adcom meeting. This has been one hell of a hit job by the FDA, from the scheduling and early announcement for Lyfgenia, all the way back to the fall of '21.

IMO, the FTC should be examining anti-trust action against the FDA.

515,583 for an avg of 0.16227, currently down some 76k+...just lovely. The collapse of this deal w Pegasus is my final straw...lol, really. Holding until I have LT gains to offset the dump.

I've never sold any KOAN, but did sell and rebought some TXHD [?] (Can't recall the exact..) back "in the day" back to back. So I might come back to clear that....but I ain't leavin yet either.

Oh, of course.

It'll moon out someday, I'm not worried about any of that.

80% is ...wow.

"several more to go"

Say what?

12.13.2023 - 12.08.2023

782,500 new shares, restricted.

Outstanding Shares
86,623,596
12/08/2023
Restricted
54,560,665
12/08/2023
Unrestricted
32,062,931
12/08/2023
Held at DTC
31,265,725
12/08/2023

Bollocks...Pegasus terminated based on Resonate Blend's failure to perform.

https://www.otcmarkets.com/filing/html?id=17119345&guid=2QJ-kn8STt5PB3h

This is the best I can find:

"The FDA issued a rare disease priory review voucher (PRV) accompanying the approval for Casgevy but not for Lyfgenia. Companies can use these vouchers to expedite FDA’s review of other drugs.

Analysts at Cantor suspected that because bluebird already got a PRV on Zynteglo, which is a twin therapy to Lyfgenia, the FDA may have viewed the request for a new PRV as double-dipping."

https://www.fiercepharma.com/pharma/fda-approves-bluebird-sickle-cell-disease-gene-therapy-can-lyfgenia-overcome-crisprs-halo

I would be thrilled w a $10/sh buyout. I believe BLUE is worth far more, but nonetheless.

I expect to see another class-action investigation by Pomerantz, but it won't go anywhere. It's not deserved.

But given the profile of this race, it's absurd that the FDA would do this.

No reason trading shouldn't be at $5, with all three drugs. The lack of PRV is mind-boggling, given the indication of 12 yrs+. Monday is going to be interesting.

Thanks, thought I was going crazy, missing something I should've seen, when it fact it was never said. It SEEMS like the FDA is out to get BLUE.

FDA tracker still has it on their calendar for the 20th. https://www.fdatracker.com/fda-calendar/

I'm curious if the cost of the crispr/vertex includes the required month long hospital stay. I bet it doesn't.

After the unsubstantiated claim by the FDA of blood cancer that caused the reorg of BLUE to BLUE and 2Seventy and the resolution of that, this is absolutely obscene to include the black box warning. An absolutely obscene course of action.

I have a question - did I miss the FDA announcing somewhere that they would be making this decision on BLUE before the 12/20 date previously published?

I do have a second question - as recently as June of 2023, BLUE's website listed "multiple undisclosed" in its pipeline. What happened to those?

Approval will be had, making the run 3/3. The big breaker will be pricing reveal and contrast against whatever CRSPR/Vertex do. I'm anticipating $10 by end of month/year. My conviction is even more so given that practically nobody is talking about Blue. Absolutely my biggest position ever, value wise. IMO, Blue will never see $3.50 again, let lone the 2s!

11.16.23 - 10.20.23 - No changes

Authorized Shares
200,000,000
10/20/2023
Outstanding Shares
85,841,096
10/20/2023
Restricted
53,778,165
10/20/2023
Unrestricted
32,062,931
10/20/2023

That would be lovely.

...and again, new 52 week low.

Been quite the sell-off, as you predicted. But with yesterday's 8-K w the pre-sale of the PRV, this is looking really nice.

10.23.23 - 10.20.23 - No changes

Authorized Shares
200,000,000
10/20/2023
Outstanding Shares
85,841,096
10/20/2023
Restricted
53,778,165
10/20/2023
Unrestricted
32,062,931
10/20/2023

10.09.23 - 10.03.23 - 3 million added, all restricted
Authorized Shares
200,000,000
10/06/2023
Outstanding Shares
85,841,096
10/06/2023
Restricted
53,778,165
10/06/2023
Unrestricted
32,062,931
10/06/2023

092023 - 091523 - 330k news shares; Restricted

Authorized Shares
200,000,000
09/15/2023
Outstanding Shares
82,841,096
09/15/2023
Restricted
50,778,165
09/15/2023
Unrestricted
32,062,931
09/15/2023

09.08.2023 - no changes

Authorized Shares
200,000,000
09/08/2023
Outstanding Shares
82,511,096
09/08/2023
Restricted
50,448,165
09/08/2023
Unrestricted
32,062,931
09/08/2023

8.27.23 -> 08.25.23 - 762,500 new, restricted.

Authorized Shares
200,000,000
08/25/2023
Outstanding Shares
82,511,096
08/25/2023
Restricted
50,448,165
08/25/2023
Unrestricted
32,062,931
08/25/2023

8.24.23 - 8.18.23 - Unchanged

Authorized Shares
200,000,000
08/18/2023
Outstanding Shares
81,748,596
08/18/2023
Restricted
49,685,665
08/18/2023
Unrestricted
32,062,931
08/18/2023

Unchanged

Authorized Shares
200,000,000
08/11/2023
Outstanding Shares
81,748,596
08/11/2023
Restricted
49,685,665
08/11/2023
Unrestricted
32,062,931
08/11/2023

Unchanged

Authorized Shares
200,000,000
08/04/2023
Outstanding Shares
81,748,596
08/04/2023
Restricted
49,685,665
08/04/2023
Unrestricted
32,062,931
08/04/2023

2 weeks later, those restricted 3,282,219 are now unrestricted, and there's an increase in OS of 137,500.

Authorized Shares
200,000,000
07/28/2023
Outstanding Shares
81,748,596
07/28/2023
Restricted
49,685,665
07/28/2023
Unrestricted
32,062,931
07/28/2023

3,282,219 OS increase, restricted.

Authorized Shares
200,000,000
07/14/2023
Outstanding Shares
81,611,096
07/14/2023
Restricted
52,830,384
07/14/2023
Unrestricted
28,780,712
07/14/2023